Related Articles
NK1.1+ cells are important for the development of protective immunity against MHC I-deficient, HPV16-associated tumours
Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours
Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin
Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF
MHC class I down-regulation: tumour escape from immune surveillance? (Review)